Project Grant R03HL187204
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $121K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $247,500 under the Cardiovascular Diseases Research program (CFDA 93.837) to validate a positron emission tomography (PET) imaging probe targeting CD206-positive macrophages for idiopathic pulmonary fibrosis (IPF) diagnosis and monitoring. The project, which commenced August 15, 2025 and concludes July 31, 2027, aims to develop and validate a PET imaging agent that shares...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $1,664,696 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an optical imaging biomarker for predicting disease progression and mortality risk in early idiopathic pulmonary fibrosis. The research develops a patient-specific optical biomarker measured through minimally-invasive endobronchial polarization-sensitive optical coherence...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $747,256 under Cardiovascular Diseases Research (CFDA 93.837) on August 17, 2026, to investigate the role of METTL3 (a methyltransferase enzyme) in heart failure with preserved ejection fraction (HFpEF). The project addresses an unmet clinical need: no pharmacological therapy has been proven to improve survival in HFpEF, the most prevalent form of heart failure particularly among patients with metabolic...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, $802,156 under Project Grant R01HL183169 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of diffusion tensor magnetic resonance imaging (DTI) techniques to image the microstructure of the human right ventricle in vivo. The recipient will develop a diffusion-encoded MRI sequence compensated for...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $185,196 on January 7, 2027 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a pilot multi-center cohort study examining patient and caregiver burden in chronic limb-threatening ischemia (CLTI). Aim 1 will assess how caregiver support relates to patient outcomes including quality of life, amputation, readmission, and mortality, collecting...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $736,411 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of neutrophil-derived resistin-like molecule G (RELMG) in arrhythmia pathogenesis and prevention. The research examines RELMG's mechanism of action and therapeutic potential in reducing ventricular tachycardia and atrial fibrillation following...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $797,124 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop pseudouridine synthase 7 (PUS7) as a novel therapeutic target for preventing adverse cardiac remodeling and treating heart failure. The project, R01HL188041, advances preclinical findings demonstrating that PUS7 inhibition activates RNA autophagy and provides...